[go: up one dir, main page]

PE20061100A1 - Sales de fosfato de 6-dimetilaminometil-1-(3-metoxifenil)-1,3-dihidroxicliclohexano - Google Patents

Sales de fosfato de 6-dimetilaminometil-1-(3-metoxifenil)-1,3-dihidroxicliclohexano

Info

Publication number
PE20061100A1
PE20061100A1 PE2006000228A PE2006000228A PE20061100A1 PE 20061100 A1 PE20061100 A1 PE 20061100A1 PE 2006000228 A PE2006000228 A PE 2006000228A PE 2006000228 A PE2006000228 A PE 2006000228A PE 20061100 A1 PE20061100 A1 PE 20061100A1
Authority
PE
Peru
Prior art keywords
dimethylaminomethyl
dihydroxyclyclohexane
metoxyphenyl
compound
phosphate salts
Prior art date
Application number
PE2006000228A
Other languages
English (en)
Inventor
Michael Grub
Andreas Fischer
Wolfgang Hell
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20061100A1 publication Critical patent/PE20061100A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE COMPUESTOS 6-DIMETILAMINOMETIL-1-(3-METOXIFENIL)-1,3-DIHIDROXICLICLOHEXANO DE FORMULA (I), EN DONDE R1 ES OH, R2 ES OH Y R3 ES H; O R3 ES OH Y R2 ES H; Y R4 ES CH3; LOS CUALES SE PRESENTAN EN FORMA DE SUS SALES DE ACIDO FOSFORICO PREFERENTEMENTE DIFOSFORICOS Y/O ORTOFOSFORICOS; SIENDO PREFERIDO LA SAL DE ORTOFOSFATO DEL COMPUESTO RACEMICO (1RS,3RS,6RS)-6-DIMETILAMINOMETIL-1-(3-METOXIFENIL)-CLICLOHEXAN-1,3-DIOL. UN PROCESO DE PREPARACION DE DICHAS SALES QUE COMPRENDE EN HACER REACCIONAR EL CLORHIDRATO DEL COMPUESTO (I) O SU BASE LIBRE, EN ACIDO FOSFORICO EN UNA RELACION MOLAR DE 2:1 HASTA 1:2. TAMBIEN SE REFIERE A LOS POLIMORFOS DE LAS FORMAS A, B, C Y AMORFO DE LA SAL ORTOFOSFATO DEL COMPUESTO Y PROCEDIMIENTOS DE OBTENCION DE DICHOS POLIMORFOS; Y UNA COMPOSICON FARMACEUTICA PARA EL TRATAMIENTO DEL DOLOR, MIGRANA, DEPRESION Y ENFERMEDADES NEURODEGENERATIVAS
PE2006000228A 2005-02-25 2006-02-27 Sales de fosfato de 6-dimetilaminometil-1-(3-metoxifenil)-1,3-dihidroxicliclohexano PE20061100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005009217A DE102005009217A1 (de) 2005-02-25 2005-02-25 Phosphatsalze der 6-Dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxy-cyclohexanverbindungen

Publications (1)

Publication Number Publication Date
PE20061100A1 true PE20061100A1 (es) 2007-01-04

Family

ID=36090780

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000228A PE20061100A1 (es) 2005-02-25 2006-02-27 Sales de fosfato de 6-dimetilaminometil-1-(3-metoxifenil)-1,3-dihidroxicliclohexano

Country Status (18)

Country Link
EP (1) EP1851191A1 (es)
JP (1) JP2008531510A (es)
KR (1) KR20070107162A (es)
CN (1) CN101137615A (es)
AR (1) AR053145A1 (es)
AU (1) AU2006218132B2 (es)
BR (1) BRPI0606146A2 (es)
CA (1) CA2598845A1 (es)
DE (1) DE102005009217A1 (es)
IL (1) IL185468A0 (es)
MX (1) MX2007010361A (es)
NO (1) NO20074673L (es)
NZ (1) NZ556338A (es)
PE (1) PE20061100A1 (es)
RU (1) RU2007135271A (es)
TW (1) TW200640840A (es)
WO (1) WO2006089707A1 (es)
ZA (1) ZA200708153B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080039400A (ko) 2005-07-07 2008-05-07 파남 컴퍼니스 인크. 고수용성 약물의 서방성 약학 조성물
DE102007022790A1 (de) * 2007-05-11 2008-11-20 Grünenthal GmbH Axomadol zur Schmerzbehandlung bei Arthrose
WO2011029614A1 (en) * 2009-09-14 2011-03-17 Grünenthal GmbH Crystalline modifications of 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525137C2 (de) * 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
DE10146275A1 (de) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
DE10333835A1 (de) * 2003-07-24 2005-03-10 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung

Also Published As

Publication number Publication date
NO20074673L (no) 2007-10-19
NZ556338A (en) 2009-11-27
WO2006089707A1 (de) 2006-08-31
TW200640840A (en) 2006-12-01
ZA200708153B (en) 2008-10-29
JP2008531510A (ja) 2008-08-14
AU2006218132B2 (en) 2011-10-06
MX2007010361A (es) 2008-02-21
EP1851191A1 (de) 2007-11-07
CN101137615A (zh) 2008-03-05
AU2006218132A1 (en) 2006-08-31
DE102005009217A1 (de) 2006-08-31
AR053145A1 (es) 2007-04-25
BRPI0606146A2 (pt) 2009-06-02
RU2007135271A (ru) 2010-02-27
IL185468A0 (en) 2008-01-06
KR20070107162A (ko) 2007-11-06
CA2598845A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
MX2022013974A (es) Inhibidor de sos1 que contiene fosforo.
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
AR038047A1 (es) Agentes terapeuticos
ECSP066730A (es) Compuestos y procedimientos para uso
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
CO5580820A2 (es) Derivados novedosos de acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico procesos para su preparacion y composiciones farmaceuticas que los contienen
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CO6290683A2 (es) Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met
UY31384A1 (es) Novedosos compuestos heterociclicos para la inhibicion de la proteina quinasa b
GT200500060A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
UY28369A1 (es) Agentes terapéuticos
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
AR063923A1 (es) Sales del acido zoledronico, procesos de preparacion y composiciones
BRPI0717794B8 (pt) composto e composição farmacêutica de ácido 3-amino-1-propanosulfônico
ECSP088587A (es) Compuestos de piperidina 3,5-sustituida como inhibidores de renina
CR9954A (es) Derivados de pirazina
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
UY28333A1 (es) Inhibidores de caspasa y sus usos.
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros
AR076181A1 (es) Compuestos derivados de mentol y uso de los mismos como agentes activos orales y sistemicos. metodo. composicion.
BR112022010181A2 (pt) Composto tri-heterocíclico como inibidor de jak e uso do mesmo
AR131735A1 (es) Agentes terapéuticos
PE20061100A1 (es) Sales de fosfato de 6-dimetilaminometil-1-(3-metoxifenil)-1,3-dihidroxicliclohexano
ECSP066964A (es) Nuevos beta-agonistas, procedimiento para su preparación y su uso como medicamentos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed